HC Wainwright Reiterates “Neutral” Rating for Trevena (NASDAQ:TRVN)

Trevena (NASDAQ:TRVN)‘s stock had its “neutral” rating restated by equities researchers at HC Wainwright in a note issued to investors on Thursday, Marketbeat reports. They presently have a $5.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 197.62% from the stock’s current price. HC Wainwright also issued estimates for Trevena’s Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.37) EPS and Q4 2025 earnings at $0.18 EPS.

Separately, StockNews.com assumed coverage on shares of Trevena in a report on Monday, November 11th. They issued a “sell” rating for the company.

Trevena Stock Performance

Shares of TRVN stock opened at $1.68 on Thursday. The stock has a market capitalization of $1.44 million, a price-to-earnings ratio of -0.04 and a beta of 1.08. Trevena has a one year low of $1.13 and a one year high of $19.23. The company’s 50-day simple moving average is $3.05 and its 200-day simple moving average is $5.64.

Trevena (NASDAQ:TRVN) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) EPS for the quarter. The business had revenue of $0.28 million during the quarter. As a group, research analysts forecast that Trevena will post -32.25 EPS for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.